1. BLLN reported $83.5M revenue in Q3 2025, up 117% YoY. 2. Prenatal testing revenue reached $74.1M, a 102% YoY increase. 3. Oncology testing surged 664% to $8.7M in the same period. 4. Positive cash flow of $6.2M was reported for Q3 2025. 5. The company projects 92%-96% growth in full-year revenue.
FAQ
Why Very Bullish?
BLLN's enormous revenue growth and profitability signal strong market demand, reminiscent of successful biotech IPOs like CRISPR Therapeutics after their strong quarterly reports. The significant improvement in both gross margin and operating income reinforces investor confidence.
How important is it?
The robust financial performance, combined with positive guidance for future earnings, makes this news significantly impactful on BLLN's stock price.
Why Short Term?
Positive quarterly results and guidance could lead to immediate investor interest, similar to recent trends seen in biotech stocks post-earnings announcements.
BillionToOne Reports Impressive Third Quarter 2025 Results
MENLO PARK, Calif., December 9, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a leading molecular diagnostics company, has released its financial results for the third quarter ended September 30, 2025. The company reported significant growth in revenues and outlined expectations for continued success as it moves through the remainder of 2025.
Financial Highlights for Q3 2025
During the third quarter, BillionToOne achieved substantial financial milestones, including:
- Total revenue: $83.5 million, up 117% from $38.4 million in Q3 2024.
- Prenatal testing revenue: $74.1 million, reflecting a 102% increase year-over-year.
- Oncology testing revenue: $8.7 million, a remarkable 664% rise from $1.1 million in the same quarter last year.
- Gross margin: 70%, a significant increase from 53% in Q3 2024.
- Operating income: $9.6 million, recovering from a loss of ($12.6) million in Q3 2024.
- Positive cash flow: $6.2 million.
- Initial Public Offering (IPO) proceeds: Raised $314.0 million.
Performance Insights and Growth Drivers
BillionToOne's robust revenue increase was driven by a surge in testing volumes. The company accessioned 162,900 tests during the third quarter, which marked a 51% increase compared to 107,900 tests in the previous year. Moreover, the overall Average Selling Price (ASP) of tests rose by 44% year-over-year, contributing to enhanced revenue generation.
Dr. Oguzhan Atay, Co-founder and CEO of BillionToOne, commented, “This quarter reinforced our view about how a unique, innovative technology combined with disciplined execution can drive a differentiated financial profile in molecular diagnostics.” He emphasized the company’s focus on scientific integrity and its commitment to addressing clinical needs effectively.
Looking Ahead: Financial Outlook for 2025
BillionToOne anticipates significant growth for the full year 2025, projecting total revenue to be between $293 million and $299 million, which represents an impressive 92% to 96% increase compared to last year. The company expects fourth quarter revenues to be in the range of $84 million to $90 million, indicating 86% to 100% growth year-over-year. Additionally, BillionToOne forecasts positive operating income for both the fourth quarter and the entirety of 2025.
Conference Call Information
BillionToOne will host a conference call to discuss these results today, December 9, 2025, at 1:30 PM PT / 4:30 PM ET. Interested investors can register online to listen to the live and archived webcasts at BillionToOne's Investor Relations site.
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne focuses on creating accurate and accessible molecular diagnostic tests. The company utilizes its proprietary Quantitative Counting Templates™ (QCT™) platform, pioneering advancements that enable single-molecule DNA counting.
Forward-Looking Statements
This press release contains certain forward-looking statements, which include expectations of future financial performance. These statements may involve risks and uncertainties that could cause actual results to differ materially from the projections made.